What's new in transapical aortic valve implantation

TY - JOUR

T1 - What's new in transapical aortic valve implantation

T2 - clinical experience with second generation devices

AU - Conradi, L

AU - Seiffert, M

AU - Blankenberg, S

AU - Reichenspurner, H

AU - Diemert, P

AU - Treede, H

PY - 2013/6

Y1 - 2013/6

N2 - Within 10 years after transcatheter aortic valve implantation (TAVI) was first accomplished for treatment of calcified aortic stenosis, this new technology has rapidly evolved to become clinical routine. Today it may be considered standard treatment for inoperable patients with superior outcomes compared to best medical therapy. Furthermore, it represents an alternative therapeutic option compared to surgical aortic valve replacement in high-risk patients. According to current international guidelines and expert consensus statements, TAVI should be performed as a joint effort by an interdisciplinary heart team to ensure input from multiple skill sets for optimal patient outcome. Major safety concerns include neurologic complications, acute kidney injury, access site complications, procedure-related conduction disturbances, paravalvular leakage valve durability. At present, only one device for transapical TAVI is in widespread clinical use: the Edwards Sapien transcatheter valve (Edwards Lifesciences, Irvine, CA, USA). Recently, however, a number of second generation devices for transapical TAVI have been developed in order to address some of the limitations of first generation valves. In this paper, current data on second generation devices for transapical TAVI will be reviewed and ongoing trials discussed.

AB - Within 10 years after transcatheter aortic valve implantation (TAVI) was first accomplished for treatment of calcified aortic stenosis, this new technology has rapidly evolved to become clinical routine. Today it may be considered standard treatment for inoperable patients with superior outcomes compared to best medical therapy. Furthermore, it represents an alternative therapeutic option compared to surgical aortic valve replacement in high-risk patients. According to current international guidelines and expert consensus statements, TAVI should be performed as a joint effort by an interdisciplinary heart team to ensure input from multiple skill sets for optimal patient outcome. Major safety concerns include neurologic complications, acute kidney injury, access site complications, procedure-related conduction disturbances, paravalvular leakage valve durability. At present, only one device for transapical TAVI is in widespread clinical use: the Edwards Sapien transcatheter valve (Edwards Lifesciences, Irvine, CA, USA). Recently, however, a number of second generation devices for transapical TAVI have been developed in order to address some of the limitations of first generation valves. In this paper, current data on second generation devices for transapical TAVI will be reviewed and ongoing trials discussed.

KW - Aortic Valve Stenosis/therapy

KW - Cardiac Catheterization/instrumentation

KW - Clinical Trials as Topic

KW - Heart Valve Prosthesis/trends

KW - Heart Valve Prosthesis Implantation/instrumentation

KW - Humans

KW - Practice Guidelines as Topic

KW - Prosthesis Design

KW - Time Factors

KW - Treatment Outcome

M3 - SCORING: Review article

C2 - 23681137

VL - 61

SP - 341

EP - 349

JO - MINERVA CARDIOANGIOL

JF - MINERVA CARDIOANGIOL

SN - 0026-4725

IS - 3

ER -